We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 483: Stason Inspection Reveals Inadequate Investigations
In a recent Form 483 handed to Irvine, Calif.-based Stason Pharmaceuticals, the FDA makes seven observations, including calling the company’s investigations into batch noncomformances “inadequate.”